sacituzumab govitecan hziy
Sponsor Gilead Sciences, INC. · listed as GILD
sacituzumab govitecan hziy is a drug asset sponsored by Gilead Sciences, INC., listed as GILD. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT04639986. That trial is in Phase 3 and currently active not recruiting, studying Metastatic Breast Cancer. It appears across 7 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for sacituzumab govitecan hziy
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-31 | READOUT | medium | NCT04639986 |
| 2027-02-28 | READOUT | medium | NCT05382286 |
| 2027-06-30 | READOUT | medium | NCT05633654 |
Trials for sacituzumab govitecan hziy in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05089734 | Phase 3 | Active, not recruiting | 2023-11-29 | Experimental | Gilead Sciences | Non-Small Cell Lung Cancer |
| NCT04639986 catalyst | Phase 3 | Active, not recruiting | 2026-12 | Experimental | Gilead Sciences | Metastatic Breast Cancer |
| NCT05382286 catalyst | Phase 3 | Active, not recruiting | 2027-02 | Experimental | Gilead Sciences | Triple Negative Breast Cancer; PD-L1 Positive |
| NCT05633654 catalyst | Phase 3 | Recruiting | 2027-06 | Experimental | Gilead Sciences | Triple Negative Breast Cancer |
| NCT05840211 | Phase 3 | Active, not recruiting | 2028-04 | Experimental | Gilead Sciences | Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer |
| NCT05382299 | Phase 3 | Active, not recruiting | 2028-07 | Experimental | Gilead Sciences | Triple Negative Breast Cancer; PD-L1 Negative |
| NCT06486441 | Phase 3 | Active, not recruiting | 2029-06 | Experimental | Gilead Sciences | Endometrial Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More GILD catalysts